Precision Medicine World Conference- Duke University
Attend Q2 Solutions Podium Presentation at PMWC 2017-Duke
About This EventPrecision Medicine World Conference-Duke will take place on May 24-25 at Duke University's Fuqua School of Business.
Plan to join Q2 Solutions' Victor Weigman, Director, Translational Genomic, in his session, Automating Evidence-based Gene Panel Design on May 24th, where he will highlight an approach that leverages mining millions of full text genomic articles to identify disease-gene-variant relationships within a concise platform that significantly reduces inclusion time and allows for selection of markers based on treatment, prognosis and monitoring.
Learn more about the event and register to attend on event website.
Director, Translational Genomics
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.
Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.